Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Tagrix 80 mg
Osimertinib 80mg tablets – Beacon Pharmaceuticals Ltd.
Approved for adults with metastatic EGFR-mutated NSCLC — including exon 19 deletion or exon 21 L858R mutations (first-line, monotherapy or with chemotherapy), the T790M resistance mutation (second-line), adjuvant treatment after surgery in early-stage disease, and locally advanced, unresectable disease following chemoradiation.
- Clinical outcomes at a glance
38.6 mo
Median overall survival as first-line monotherapy vs 31.8 months with older EGFR-TKIs (FLAURA trial)
+9 mo
Additional median PFS when combined with chemotherapy vs osimertinib alone, with confirmed OS benefit (FLAURA2)
79%
Reduction in risk of disease recurrence or death in adjuvant early-stage EGFR-mutated NSCLC (ADAURA trial)
5
Distinct Phase III trials — FLAURA, FLAURA2, AURA3, ADAURA, LAURA — spanning every major disease stage
- Am I a candidate? — Take Decesion
1
Confirm EGFR mutation status
Requires confirmed EGFR exon 19 deletion, exon 21 L858R, or T790M mutation via an FDA-approved test. The specific mutation and treatment line (first-line vs after resistance to an earlier EGFR-TKI) determines which approved indication applies.
2
Baseline cardiac assessment
Cardiomyopathy and QTc prolongation have been reported — baseline ECG and cardiac function (ejection fraction) assessment, with periodic monitoring, is part of standard preparation.
3
Baseline lung assessment given ILD/pneumonitis risk
A baseline assessment of respiratory symptoms and lung imaging helps establish a comparison point, given the risk of interstitial lung disease/pneumonitis, which can be severe and fatal.
4
Discuss whether monotherapy or combination with chemotherapy is appropriate
For first-line advanced disease, osimertinib can be used alone or with pemetrexed and platinum-based chemotherapy — the combination shows stronger PFS and confirmed OS benefit but with substantially more frequent side effects.
Important safety information: Interstitial lung disease/pneumonitis can occur and may be fatal — promptly investigate any new or worsening respiratory symptoms. Cardiomyopathy and QTc interval prolongation have been reported; baseline and periodic cardiac monitoring is recommended. Embryo-fetal toxicity — not for use in pregnancy; effective contraception is required during treatment and for a period after the final dose.
- common side effects to know
- Diarrhea
- Rash / dry skin
- Nail toxicity / stomatitis
- Reduced appetite / fatigue
- Interstitial lung disease / pneumonitis
- Cardiomyopathy / QTc prolongation
- Trust & expertise
- FDA Approved 2015, Expanded 2018–2024
- EMA Approved 2016
- NCCN NSCLC Guidelines (Category 1)
- FLAURA / FLAURA2 / AURA3 / ADAURA / LAURA Trials
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“Osimertinib has built one of the most extensive evidence bases of any targeted therapy in oncology — five separate Phase III trials now support its use from early-stage, post-surgical disease through advanced metastatic disease with brain involvement. The FLAURA2 combination data with confirmed overall survival benefit is a genuinely important recent addition. Beacon’s Tagrix was the world’s first global generic preparation of this molecule, representing a meaningful step toward making this treatment accessible in price-sensitive healthcare settings globally.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
We covered this in full detail earlier in our conversation for the Tasso page — here’s the complete set pulled forward rather than repeating the research.
Before confirming osimertinib as your treatment
- Has my EGFR mutation been confirmed, and is it an exon 19 deletion, exon 21 L858R, or T790M resistance mutation?
- Which of the approved uses applies to me — first-line treatment, adjuvant therapy after surgery, treatment after chemoradiation, or second-line after a prior EGFR-TKI?
- If I’m starting first-line treatment for advanced disease, is monotherapy or combination with chemotherapy being recommended, and why?
- Are there clinical trials I should know about?
About lung monitoring — interstitial lung disease
- Will I have a baseline chest scan or assessment of my breathing before starting?
- What does early ILD or pneumonitis look like, and when should I call versus seek emergency care?
- Since I may already have breathing symptoms from my lung cancer, how will we distinguish drug-related lung problems from disease-related symptoms?
- If pneumonitis develops, does it always mean stopping permanently, or can it sometimes be managed with a pause and restart?
About cardiac monitoring
- Will I have a baseline ECG and cardiac function (ejection fraction) assessment before starting?
- How often will these be rechecked during treatment?
- What symptoms — irregular heartbeat, dizziness, fainting, chest pain — should prompt an urgent call?
- Am I taking other medications that could compound QTc prolongation risk?
About brain involvement, if relevant
- Do I have, or am I at risk for, brain metastases, and how does osimertinib’s CNS penetration factor into my treatment plan?
- Will brain imaging be part of my monitoring schedule?
About monotherapy vs. combination therapy, if first-line
- What do the PFS and OS differences look like between monotherapy and the chemotherapy combination for my specific situation?
- How much more intense are the side effects with the combination, and is that trade-off worth it for me?
- If I start with monotherapy, can chemotherapy be added later if needed?
About dosing and administration
- The dose is 80mg once daily — does timing matter, and should it be taken with or without food?
- What happens if I miss a dose or vomit shortly after taking it?
- Can the tablet be dispersed in water if swallowing it whole is difficult?
About managing common side effects
- Diarrhea, rash, and dry skin are common — what can help, especially early in treatment?
- Is nail toxicity or mouth sores expected, and how are these managed?
About drug interactions
- Are there strong CYP3A inducers I should avoid?
- If I’m prescribed something new by another doctor, what should they know?
About contraception and fertility
- What contraception is required during treatment and after stopping?
About monitoring response
- What imaging schedule will track whether this is working?
- How soon might we expect to see signs of response?
About the longer road
- If osimertinib stops working, what would typically be considered next?
- Are there patient assistance programs through AstraZeneca if cost is a concern?
A practical tip: Because osimertinib now spans five distinct approved uses across very different disease stages, it’s worth asking your oncologist to explain specifically which trial data applies to your situation — FLAURA, FLAURA2, AURA3, ADAURA, or LAURA — since the expected benefits, monitoring intensity, and monotherapy-versus-combination decision look quite different depending on exactly where you are in your disease course.
compare with other therapies
We covered this comparison in full detail earlier in our conversation for the Tasso page — here are the key findings pulled forward concisely.
Both are FDA-approved first-line options from dedicated trials
| Osimertinib monotherapy | Osimertinib + chemotherapy | |
|---|---|---|
| Pivotal trial | FLAURA | FLAURA2 |
| FDA approval | 2018 (first-line) | 2024 |
| Regimen | Osimertinib 80mg daily alone | Osimertinib plus pemetrexed and platinum-based chemotherapy |
Efficacy — the combination shows a clear, measurable advantage
- 24-month progression-free rate: 41% monotherapy vs 57% combination
- Median duration of response: 15.3 months monotherapy vs 24.0 months combination — a substantially longer duration
- Objective response rate: 76% monotherapy vs 83% combination
- Overall survival: More mature FLAURA2 data confirmed statistically significant and clinically meaningful OS improvement with the combination — not just a PFS signal
The duration-of-response gap (24.0 vs 15.3 months) is arguably the most clinically meaningful number — when the combination works, it keeps working considerably longer.
Side effects — more than double the serious adverse events
Grade 3 or higher adverse events: 64% combination vs 27% monotherapy — more than doubled, largely from expected chemotherapy-related hematologic and gastrointestinal toxicities. The combination brings the full burden of platinum-based chemotherapy (nausea, fatigue, blood count suppression, hair loss, infusion logistics) on top of osimertinib’s own profile.
Brain metastases
Benefit from the combination was observed including in patients with baseline CNS metastases — worth raising specifically if brain involvement is part of your situation.
Where the choice tends to land
Favor monotherapy when tolerability and quality of life are a high priority, a patient has comorbidities making chemotherapy riskier, or infusion-based treatment is strongly preferred to be avoided.
Favor the combination when maximizing progression-free survival and durability is the priority, the patient is fit enough for chemotherapy, and the confirmed OS benefit is weighted heavily — since this represents a more important outcome than PFS alone.
Bottom line
The combination clearly outperforms monotherapy on response rate, duration, PFS, and — with mature data — overall survival, at the cost of more than double the rate of serious adverse events. Neither option is simply “better” in isolation; the decision genuinely depends on how a specific patient weighs additional survival benefit against a meaningfully more intensive treatment burden. This is a conversation worth having directly and honestly with your oncologist, particularly given that the now-confirmed survival benefit changes the calculation compared to when only PFS data was available.
How does testing work
We covered this in full detail earlier in our conversation for the Tasso page — here are the key points pulled forward rather than repeating the research.
What EGFR does and how cancer hijacks it
EGFR (epidermal growth factor receptor) is a surface receptor that, when activated, triggers internal signaling driving cell growth and survival. In a meaningful subset of NSCLC, activating EGFR mutations — most commonly exon 19 deletions or exon 21 L858R — cause this kinase to become permanently switched on, driving uncontrolled tumor growth.
Why first and second-generation EGFR inhibitors eventually fail
Earlier EGFR drugs (gefitinib, erlotinib, afatinib) block the ATP-binding pocket of the EGFR kinase. They were effective initially, but a specific, predictable resistance mechanism emerged: the T790M mutation alters the shape of the ATP-binding pocket just enough to reduce how well first and second-generation drugs bind there, while still allowing the kinase to function — letting cancer cells escape the drug while keeping their growth machinery intact.
How osimertinib was specifically designed to solve this
Osimertinib is a third-generation, irreversible EGFR-TKI that potently and selectively inhibits both the original activating mutations and the T790M resistance mutation. Its chemical structure was designed to accommodate the altered shape of the T790M-mutated binding pocket — where earlier drugs lost their grip, osimertinib maintains effective binding despite the structural change.
By binding covalently (irreversibly) to a specific cysteine within the EGFR kinase’s ATP-binding pocket, osimertinib permanently disables individual EGFR kinase molecules rather than competing transiently with the cell’s own ATP.
Why selectivity for mutant over wild-type EGFR matters
Osimertinib was optimized to have much weaker activity against normal, wild-type EGFR (found in healthy cells) compared to the mutant, cancer-driving forms — helping explain its somewhat more manageable side-effect profile compared to some earlier-generation EGFR inhibitors, which had more pronounced effects on normal EGFR-dependent tissues like skin and gut.
Why it crosses into the brain
Osimertinib’s specific physical and chemical properties allow meaningful penetration across the blood-brain barrier — a property not equally shared by all EGFR inhibitors. This explains its strong CNS activity in patients with brain metastases, and is part of why it has become the preferred starting point rather than a fallback option.
Why this design anticipates resistance rather than just reacting to it
Using osimertinib from the start means never giving the cancer the opportunity to develop T790M resistance against a first-generation drug in the first place — the drug’s ability to block both the original activating mutations and T790M simultaneously is precisely why it’s now preferred as first-line therapy rather than reserved only for patients who’ve already developed resistance.
The bigger picture
Osimertinib represents a genuinely strategic piece of drug design: built to anticipate and neutralize the most common, predictable way cancer cells escape earlier-generation EGFR-targeted therapy, while additionally crossing into the brain and sparing normal EGFR more than its predecessors — which is exactly why it has become the preferred starting point for EGFR-mutated NSCLC rather than a fallback option.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
